Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

计划入组 7 人 · 首次发布于 2021 年 11 月 24 日

Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)

计划入组 123 人 · 首次发布于 2013 年 11 月 20 日

Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)

计划入组 132 人 · 首次发布于 2017 年 5 月 8 日

Adena C 500

ADENTA SIA

Latvia

Cadent Therapeutics, Inc.

United States

GRUPO ESPAÑOL DE TRATAMIENTO DE TUMORES DE CABEZA Y CUELLO

Spain

Novel Antibody-Drug Conjugate Achieves 85% Response Rate in Rare Blood Cancer Trial

FDA Approves Sanofi's Enjaymo: First Targeted Therapy for Rare Blood Disorder CAD

AbbVie Submits FDA Application for Pivekimab Sunirine to Treat Rare Blood Cancer BPDCN